Zoetis Inc. (NYSE:ZTS) Shares Sold by Citizens National Bank Trust Department

Citizens National Bank Trust Department cut its position in Zoetis Inc. (NYSE:ZTS) by 1.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,130 shares of the company’s stock after selling 80 shares during the quarter. Citizens National Bank Trust Department’s holdings in Zoetis were worth $1,162,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. AMF Tjanstepension AB raised its position in Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after acquiring an additional 20,001 shares in the last quarter. Howard Capital Management Group LLC boosted its holdings in shares of Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Zoetis by 8.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 55,696 shares of the company’s stock valued at $10,882,000 after acquiring an additional 4,107 shares in the last quarter. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Zoetis by 10.6% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,966 shares of the company’s stock worth $579,000 after purchasing an additional 284 shares in the last quarter. Finally, Raleigh Capital Management Inc. lifted its stake in Zoetis by 128.5% in the third quarter. Raleigh Capital Management Inc. now owns 361 shares of the company’s stock valued at $71,000 after acquiring an additional 203 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ZTS shares. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Stifel Nicolaus cut their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average price target of $214.90.

Zoetis Trading Up 0.3 %

ZTS opened at $156.92 on Thursday. The stock has a market capitalization of $70.27 billion, a price-to-earnings ratio of 28.69, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a 50-day simple moving average of $167.29 and a 200 day simple moving average of $178.29.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Analysts predict that Zoetis Inc. will post 6.06 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.